Summary by Moomoo AI
Intelligent Bio Solutions Inc., a medical technology company listed on Nasdaq under the symbol INBS, announced on April 11, 2024, the expansion of its intellectual property portfolio with the grant of a new European patent for its subsidiary, Intelligent Fingerprinting Limited. The patent, which has unitary effect, covers the DSR-Plus Cartridge Reader, a device that facilitates non-invasive, rapid drug screening through fingerprint sweat analysis. This technology is particularly useful in workplace and safety-critical environments. The European patent enables the company to enforce its rights in 17 European countries, marking a significant step in Intelligent Bio Solutions' strategy to expand its global presence and offer its advanced solutions to a wider market. The company's CEO, Harry Simeonidis, expressed enthusiasm for the expansion into the European market and the potential to enhance workplace safety and health. The DSR-Plus Cartridge Reader is noted for its efficiency, providing results in less than ten minutes, and is part of the company's broader aim to revolutionize portable testing across various applications.